within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01C_HypothalamicHormones.H01CC03_Elagolix;

model Elagolix
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.46,
    Cl = 3e-06,
    adminDuration = 600,
    adminMass = 150 / 1000000,
    adminCount = 1,
    Vd = 0.167,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0205,
    Tlag = 10.020000000000001,
    Vdp = 0.052,
    k12 = 9.805555555555556e-06,
    k21 = 9.805555555555556e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Elagolix</td></tr><tr><td>ATC code:</td><td>H01CC03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>150</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>167</td><td>L</td></tr>
    <tr><td>clearance:</td><td>10.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Elagolix is a non-peptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist used primarily for the management of moderate to severe pain associated with endometriosis in women. It is approved by the FDA for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy premenopausal women following oral administration.</p><h4>References</h4><ol><li><p>Shebley, M, et al., &amp; Mostafa, NM (2020). Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. <i>Clinical pharmacokinetics</i> 59(3) 297–309. DOI:<a href=\"https://doi.org/10.1007/s40262-019-00840-7\">10.1007/s40262-019-00840-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31749075/\">https://pubmed.ncbi.nlm.nih.gov/31749075</a></p></li><li><p>Zhang, X, et al., &amp; Wen, Q (2024). Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population. <i>Clinical pharmacokinetics</i> 63(9) 1357–1370. DOI:<a href=\"https://doi.org/10.1007/s40262-024-01402-2\">10.1007/s40262-024-01402-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39060899/\">https://pubmed.ncbi.nlm.nih.gov/39060899</a></p></li><li><p>Abbas Suleiman, A, et al., &amp; Mostafa, NM (2020). Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 9(11) 639–648. DOI:<a href=\"https://doi.org/10.1002/psp4.12560\">10.1002/psp4.12560</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32945631/\">https://pubmed.ncbi.nlm.nih.gov/32945631</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.H.H01CC03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Elagolix;
